Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Massachusetts court hears arguments in lawsuit alleging Meta designed apps to be addictive to kids - 2The capacity to understand people on a profound level: Exploring Life's Intricacies
- 3Explainer-What will change with the US reclassification of marijuana?
- 4Impact of NIH funding reductions felt in cancer and infectious disease trials
- 5Step by step instructions to Keep up with the Life span of Your Kona SUV's Battery Duration
- Vote in favor of the pasta that makes good dieting pleasant!
- Stolen Renoir, Cézanne and Matisse were probably uninsured, market sources say
- Avoid Slam: Exploring the Pickup Truck Transformation
- Russia patents space station designed to generate artificial gravity
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
- Want to read more in 2026? Here's how to revive your love of books
- 5 Breakout Stars in Ongoing television Series
- The Specialty of Cleaning up: Change Your Space and Brain
